Thermal ablation in adrenal disorders: a discussion of the technology, the clinical evidence and the future

Padraig Donlon and Michael Conall Dennedy

Purpose of review
To summarise the emerging role of thermal ablation as a therapeutic modality in the management of functioning adrenal tumours and metastases to the adrenal gland.

Recent findings
Observational evidence has demonstrated the benefit of thermal ablation in (i) resolving adrenal endocrinopathy arising from benign adenomas, (ii) treating solitary metastases to the adrenal and (iii) controlling metastatic adrenocortical carcinoma and phaeochromocytoma/paraganglioma.

Summary
Microwave thermal ablation offers a promising, minimally invasive therapeutic modality for the management of functioning adrenocortical adenomas and adrenal metastases. Appropriate technological design, treatment planning and choice of imaging modality are necessary to overcome technical challenges associated with this emerging therapeutic approach.

Keywords
adrenal adenoma, adrenal tumour, Cushing’s syndrome, microwave thermal ablation, primary aldosteronism

INTRODUCTION
The past decade has seen the widespread application of minimally invasive technologies to thermally ablate solid tumours within large organs, using radiofrequency electrical energy (RFA), microwave thermal ablation (MWA), cryoablation, high-intensity focused ultrasound and laser [1]. Thermal ablation has largely been applied within the clinical setting to inoperable malignancies or metastases within the liver or kidney, with more recent applications to tumours of the bone, lung and breast [2,3]. The modality is largely safe, well-tolerated and efficacious within these settings. It is usually delivered using radiological image-guidance, most commonly via Computed Tomography (CT) or ultrasound [4]. However, thermal ablation remains an emerging therapy and the majority of currently supporting evidence comes from longitudinal cohort studies. Large randomised controlled trials are lacking in the area, although important studies such as the Liver resection surgery versus thermal ablation for colorectal LiVer MetAstases trial aim to fill this gap [5,6].

Although the clinical focus of thermal tumour ablation has been malignancy, this therapeutic modality offers exciting and paradigm-shifting potential to provide definitive therapy to benign endocrine tumours, particularly within the context of systemic endocrinopathy [7–10]. In this regard, several case series and small observational studies have examined the efficacy and safety of both RFA and MWA in the setting of thyroid, parathyroid and adrenal tumours [11]. This article focusses on the application of microwave and radiofrequency thermal ablation to the adrenal gland and provides (i) a review of the technology behind thermal ablation, (ii) an overview of its clinical use in adrenal disorders and (iii) a brief discussion of future direction.
The objective of thermal ablation is to produce a core tissue temperature >50°C in order to induce cell death by coagulative necrosis [12]. The principle therapeutic challenge relates to reaching a core temperature that covers the entire tumour volume, but which does not damage adjacent critical tissues or organs. In addition to coagulative necrosis within the so-called ablation zone, an inflammatory infiltrate is typically seen within the intervening transition zone between the area of effective ablation and adjacent healthy tissue (Fig. 1) [13]. Immune infiltrates of monocyte/macrophages, neutrophils, dendritic cells, natural killer cells, and lymphocytes have all been demonstrated within the transition zone across varying tissue types following both RFA and MWA [14]. Interestingly similar immune infiltrates have also been described in metastatic deposits remote from the ablated tumour site, as well as within the circulating blood following ablation [13,15]. Several mechanisms have been proposed for this response including the effect of tumour ablation to cause a local release of damage associated molecular patterns, such as heat shock proteins and HMGB1. When released extracellularly, these molecules act as chemoattractant chemokines that stimulate a local and sometimes systemic immune response [16]. The immune response to thermal ablation is an exciting area of research and is hypothesised to play a role in modulating spontaneous regression of distant tumour metastasis following ablation of a primary tumour or metastatic lesions [17]. Tumour specific T cell responses observed following thermal ablation therapy have been associated with increased tumour-free survival in humans [18]. Supporting data for this association, generated in animal models demonstrate resistance to graft re-growth in animals subjected to a tumour rechallenge following previous thermal ablation [17]. Tumour immunoediting is an interesting feature of thermal ablation that offers the potential for systemic augmentation with immune therapy in order to maximise patient outcomes.

**THERMAL ABLATION: TECHNOLOGY AND APPROACH**

Systems for delivering RFA and MWA are both illustrated in Fig. 1. Briefly, both systems use an energy generator to transmit electrical or microwave energy at varying doses via an applicator probe to a tissue targeted for thermal ablation. Conversion to thermal energy occurs at tissue-level and relies upon tissue properties, such as water content (MWA) and electrical impedance (RFA). Applicator probes are usually rigid, although flexible applicator designs are also available [19]. Probes are typically guided to their target tissue/tumour through an introducer needle using radiological image guidance via CT or ultrasound. Pulsed (RFA) or constant (MWA) energy is delivered to the target over a period of 5–20 min, with the aim of reaching a core temperature >50°C within the targeted tissue or tumour, delivered over a cumulative time period of 4–5 min.

Although the general principle of delivering thermal energy to a targeted tissue or tumour is similar between both systems, the technology and the manner of heating differs considerably. Radiofrequency has traditionally been more commonly utilised within the clinical setting, yet MWA offers several advantages and the technology to effectively and precisely deliver MWA has recently advanced. An illustration of the heating patterns for RFA and MWA is provided in Fig. 2 and a comparison of both modalities is provided in Table 1 [4].

Radiofrequency ablation has principally been used to target hepatic tumours. However, the past decade has seen its indications expand to other organs/tissues. Temperatures ranging between 60 and 100°C are generated at the applicator tip, via alternating current, at frequencies from 100–500 kHz. Effective RFA requires that targeted tissue has low electrical impedance. Consequently, RFA is limited technically by the following: (i) heating is only achieved immediately adjacent to the applicator and (ii) high temperatures at the applicator tip dehydrate tissue, increases electrical impedance and hinders energy penetration into circumjacent tissue [19]. This is typically overcome by delivering pulsed
RFA over a more prolonged duration in order to achieve sufficient penetration. Challenges of tissue penetration are further compounded by heat sink, whereby applied temperatures are reduced by adjacent large blood vessels absorbing heat and carrying it away through the effects of blood flow, thereby decreasing the hyperthermic efficiency of RFA [20].

MWA produces heat through electrical hysteresis. It provides better tissue healing and efficiency when compared to RFA and is less susceptible to heat sink. An electromagnetic field between 900 and 2500 MHz is delivered to targeted tissues via a coaxial cable. This field causes polar molecules (usually water) to constantly realign with the oscillating
FIGURE 2. Ablation probe heating patterns; (a) This illustration depicts the general heating pattern demonstrated by each modality and the effects of proximal vasculature. (b) Mathematical models can be used to predict heating patterns for each modality and device in adrenal tissue. The simulations illustrate thermal profiles following ablation with a 15-G monopolar RF applicator with a 10-mm active electrode following 2 and 10 min heating. The applied RF power was adjusted to constraint temperature at the electrode-tissue interface within the range 90–97°C. MWA simulations are for a 14-G water-cooled directional applicator and a 15-G water-cooled omni-directional MWA applicator [39]. Both MWA applicators operate at 2.45 GHz and simulations are shown for 30 W power delivered to the applicator for 5 min. Simulation figures courtesy Faraz Chamani, Austin Pfannenstiel, Punit Prakash. MWA, microwave ablation.

Table 1. Differences between radiofrequency ablation (RFA) and microwave ablation (MWA)

|                  | RFA                                                                 | MWA                                                                 |
|------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|
| Heating mechanism| Results in hyperthermia via electric current which relies upon tissue conductivity and ion content. (−) | Results in hyperthermia via electromagnetic energy which relies upon tissue polar molecule (water) content. (+) |
| Grounding pad    | Requires the use of grounding pads which can result in burns (−)      | Does not require grounding pads (+)                                   |
| Heating efficiency| Inefficient at higher temperatures due to tissue desiccation resulting in increase impedance (−) | Rapid heating and little effect of tissue desiccation (+)             |
| Heat sink        | Heat sink effect can be a major issue for well vascularised organs (−)| Less susceptible to heat sink (+)                                    |
| Procedure time   | More procedural time (−)                                             | Less procedural time (+)                                             |
| Ablation volume  | Smaller ablation sizes (−)                                           | Larger ablation sizes (+)                                            |
| Ablation zone    | Unpredictable (−)                                                    | Predictable, allowing for better treatment planning (+)              |
| Procedural pain  | Higher level of pain (−)                                             | Less level of pain (+)                                              |

Advantages (+), Disadvantages (−).
electric field. Molecular rotation increases kinetic energy that is converted to heat within targeted tissues. Heat conductance using this modality favours tissues with a high percentage of water such as solid organs and tumours [21,22]. Microwave systems typically provide better tissue penetration compared to RFA as they do not require paths of low electrical impedance [23]. They can also produce larger, more precise, spherical ablation zones within a shorter application time, using constant rather than pulsed energy delivery [24**,25**,26**]. Multiple synergistic antennae can also be synchronously used to deliver focused energy to single large tumours or even to simultaneously target multiple tumour loci [27].

Microwave however is not without its challenges. Generation and transmission of microwave energy have traditionally been difficult to achieve and must be carried in coaxial cables, which of wider gauge than that of the simple wires used in RFA applicators [28]. Cable heating presents a greater challenge for MWA, when compared to RFA and therefore these systems must be cooled, using water or gas, both of which add to the complexity and diameter of the applicator antennae [22,25**,28, 29**,30,31]. It is due to these complexities that the advancement and broader use of MWA in the clinic has lagged behind RFA [32].

**ADRENAL TUMOURS AND THE ROLE OF THERMAL ABLATION**

Tumours of the adrenal gland have an estimated prevalence of 3–10% in the population aged >50 years and are commonly picked up as so-called incidentalomas on abdominal imaging [33]. Overall, 80% of adrenal incidentalomas are of no clinical significance [34]. For the remaining 20%, surgical resection/adrenalectomy is the definitive treatment of choice where indicated [35–38] The following tumours of the adrenal gland are typically resected: (i) benign functioning unilateral tumours associated with systemic endocrinopathy [39]; (ii) adrenocortical carcinoma (ACC) [38]; (iii) phaeochromocytoma [40]; (iv) solitary metastasis to the adrenal gland [41] (Table 2). Bilateral functioning tumours of the adrenal are usually not amenable to resection due to the lack of widespread, feasible options for adrenal sparing surgery compounded by the difficulty in identifying and localising specific hyperfunctioning regions within the adrenal [42]. Uncommonly, where severe systemic endocrinopathy is driven by disease in both glands, bilateral adrenalectomy is undertaken [43,44]. However this involves a considerable prognostic trade-off between patient-specific implications of endocrinopathy, which must be balanced with the inevitable complication of lifelong adrenocortical insufficiency [36].

Adrenalectomy, where possible, represents the current treatment of choice for definitive management of adrenal disease. In this regard the approach to adrenalectomy has advanced considerably over the past two decades [45]. Laparoscopic adrenalectomy is now the surgical technique of choice, with some centres offering retroperitoneoscopic approaches [46]. Although not widely available, adrenocortical sparing surgery has also been undertaken for bilateral disease localised within the adrenal [46,47]. Nonetheless, adrenalectomy remains a skilled surgical procedure, requiring general anaesthetic within an often high-risk population and representing the resource-intensive costs associated with hospitalisation, operating room use and the personal and economic implications of the recovery period.

Thermal ablation of the adrenal gland may overcome some surgery associated challenges. This percutaneous and minimally invasive technique offers the potential for fast and effective therapy to disrupt adrenal tumours while reducing patient discomfort, cost and hospitalised days [48**]. Its indications are additionally broadened to those unwilling or unfit for adrenalectomy due to co-morbidity [49]. It is in this regard that thermal therapy has been trialed amongst small cohorts as a (i) minimally invasive alternative to definitive management of benign adrenal adenomas [39,50–56], (ii) adrenal metastases in patients unsuitable for surgery and [3,10,48**,57–59] (iii) for local management of metastatic adrenal cancers [60**,61**,62,63**].

Advancement of thermal ablation of the adrenal gland through specifically designed precision application systems provides the opportunity to selectively disrupt localised, diseased tissue within one or both adrenal glands while leaving nontargeted adjacent normal tissue unaffected - thereby minimising the risk of postprocedural adrenocortical insufficiency [24**]. This makes thermal therapy a potentially paradigm shifting candidate for definitive management of unilateral adrenal tumours, as well as offering an exciting option for definitive management of endocrinopathy driven by bilateral localised adrenal disease [24**]. However, significant progress must be made in terms of applicator design and generation of clinical evidence before these clinical applications can be introduced in a safe and consistent manner.

**ADRENAL ABLATION: CURRENT CLINICAL EVIDENCE**

Current evidence supporting thermal ablation of adrenal disorders arises from small observational
Table 2. Previous literature of adrenal thermal ablations and their outcomes

| Author               | Year | Ablation | Tumour                  | Size          | Patient No. | Residual | Recurrence | Biochemical Resolution | Complications                                          | Follow Up |
|----------------------|------|----------|-------------------------|---------------|-------------|----------|------------|------------------------|--------------------------------------------------------|-----------|
| Arima et al. [51]    | 2007 | RFA      | Adenoma, Cushing’s      | 2.0–3.5 cm    | 4           |          |            | 100%                   | Hypertensive crisis (25%), Pneumothorax (25%)          | 46 months |
| Nishi et al. [52]    | 2012 | RFA      | Adenoma, Cushing’s      | 3 cm          | 1           |          |            | 100%                   | Adrenal hypofunction which recovered after 18 months | 5 years   |
| Chini et al. [3]     | 2004 | RFA      | Metastasis to adrenal   | 2.8 cm        | 1           | 100%     |            |                        | Severe hypertension (249/140 mm Hg) and narrow complex tachycardia (140 bpm) |          |
| Frenk et al. [57]    | 2017 | RFA, MWA,Cryo | Metastasis to adrenal | <5 cm        | 38          | 4%       | 24%        |                        | Hypertensive Crisis (57%), Intermittent urinary retention (6%), Acute cholecystitis (2%), Pneumothorax (2%), | 37 months |
| Hasegawa et al. [58] | 2015 | RFA      | Metastasis to adrenal   | 1.2–8.2 cm    | 35          | 6%       | 23%        |                        | Acute Renal Failure (3%), Heart Failure (3%), Hypertensive Crisis (66%), Hepatic hematoma (3%) | 30.1 months |
| Liu et al. [48**]    | 2020 | RFA      | Metastasis to adrenal   | 1–9 cm        | 29          | 24%      |            |                        | Ascites (3.5%), Pain (28%), Ventricular fibrillation (3.5%), Hypertensive crisis (13.7%), Bradycardia (3.5%) | 24.5 months |
| Wolf et al. [64]     | 2012 | RFA, MWA | Metastasis to adrenal   | 2–8 cm        | 19          | 5%       | 15% after first ablation, 5% after second ablation |                        |                                                      | 14 months |
| Mendiratta-Lala et al. [53] | 2010 | RFA      | All Neoplasm, (APA, cortisol-secreting, testosterone-secreting) | <3.2 cm      | 13          |          |            | 100%                   | Hypertension (15.4%), Adrenocortical insufficiency recovered after 15 months (8%) | 41.4 months |
| Mayo-Smith et al. [11] | 2004 | RFA      | All Neoplasm (metastases, PA, APA) | 1–8 cm | 12 | 15.4% | | | Retroperitoneal hematoma (8%) | | 11.2 months |
| Abbas et al.         | 2013 | RFA, Cryo | APA                     | 1.5–2.5 cm    | 5           |          |            | 60%                    | Hypertensive crisis (100%)                             | 12 months |
| Liu et al. [39]      | 2016 | RFA      | APA                     | 1.6 cm        | 24          |          |            | 96%                    | Pneumothorax (4.2%), Retroperitoneal hematoma (12.5%) | 21.2 months |
| Author                  | Year | Ablation | Tumour                | Size  | Patient No. | Residual | Recurrence | Biochemical Resolution | Complications                                                   | Follow Up |
|------------------------|------|----------|-----------------------|-------|-------------|----------|------------|------------------------|---------------------------------------------------------------|-----------|
| Liu et al. [10]        | 2016 | RFA      | APA                   | 1.5 cm| 36          |          |            | 92%                    | Pneumothorax (8%), Retroperitoneal hematoma (8%), Infected retroperitoneal hematoma (3%) | 6.2 years |
| Sarwar et al. [55]     | 2016 | RFA      | APA                   | <4 cm | 12          |          |            | Cured hypertensive (17%), Fewer antihypertensives (58%) |                                                            | 463 days  |
| Szejnfeld et al. [56]  | 2015 | RFA      | Cushing’s Syndrome    | 1.5–3.4 cm | 11       |          | 100%       |                                                       |                                                              | 24 months |
| Delijou et al. [62]    | 2018 | RFA      | Metastatic PPGL       | 2    |             |          |            |                                                       | Hypertensive Crisis (4.8%), Post ablation bleeding (4.8%), argon gas embolism (4.8%) |           |
| Kohlenberg et al. [63] | 2019 | RFA, Cryo| Metastatic PPGL       | 5.5 cm | 31 patients, 123 lesions, 80 lesions examined | 14%     |            |                                                       | Pain, fever (14%), Gastrointestinal bleeding (3.2%), Hypertensive crisis (14%) | 60 months |
| Fintelmann et al. [59] | 2016 | RFA, MWA | Metastasis to adrenal | 0.7–11.3 cm | 57       |          |            |                                                       | Hypertensive crisis (43%), Adrenal insufficiency (22%), Ventricular tachycardia (1.4%) |           |
| Ren et al. [68]        | 2016 | MWA      | All Neoplasms         |       | 33          |          |            | 15.2%                  | 100%                                         | 24 months |
| Liu et al. [60]        | 2019 | RFA      | ACC                   | 6.3 cm| 1           |          |            |                                                       |                                               | 12 month  |
| Veltri et al. [61]     | 2020 | RFA, MWA | ACC                   | 14–43.5 cm | 16       |          |            | 21.8%                  | Intrahepatic hematoma (6.2%)                                      | 42 months |

ACC, Adrenocortical carcinoma; APA, aldosterone producing adenoma; Cryo, cryoablation; MWA, microwave ablation; PA/PGL, pheochromocytoma/paraganglioma; RFA, radiofrequency ablation.
clinical studies and case series using RFA, MWA and cryoablation (Table 2). These studies have documented short and intermediate term outcomes for unilateral aldosterone producing adenomas (APA) [8,39,50,53,55,56], cortisol secreting adenoma [51–53], Adrenocorticotropic Hormone-dependent Cushing’s disease [53,56], adrenal metastases and pheochromocytoma [60**,61**,62,63**]. The approach to ablation has not been consistent across all studies and definitions of clinical response to therapy vary in accordance with underlying pathology [30–47,48**]. For malignancy and metastasis to the adrenal, success is determined by change in tumour characteristics on imaging, specifically (i) tumour-size reduction, (ii) absence of local tumour progression or (iii) progression/recurrence-free survival [11,48**,51,57,58,63**,64]. For APA, pheochromocytoma and Cushing’s syndrome, success is additionally determined by biochemical resolution/improvement of endocrinopathy and resolution of hypertension [51–54,65]. In spite of the inhomogeneity of treatment approach and lack of standardised outcome reporting, the current data are encouraging in support of adrenal ablation. A summary of specific studies in which adrenal ablation has been applied is provided in Table 2.

Outcomes for biochemical resolution of endocrinopathy in the setting of unilateral APA, or cortisol-secreting adenoma is high for studies using both RFA and MWA. In general, all studies have demonstrated cure of endocrinopathy in both settings for 75–100% of cases after a single ablation and 100% following repeated ablation. For APA, complete resolution of hypertension occurs in approximately 45%, with complete or partial resolution in 90% following thermal ablation. This is comparable with unilateral adrenalectomy [8,39,51,52,66,67].

For metastases to the adrenal gland, both MWA and RFA have demonstrated high efficacy of tumour ablation, demonstrating postprocedural absence of residual tumour in fewer than 25%, with similarly low recurrence rates (≤25%). Overall survival rates have not been evaluated due to the lack of a comparator and the heterogeneity of the underlying primary malignancy in these studies [3,48**,57,58,64,68].

Staged, bilateral RFA was undertaken in a small case series of 5 patients with severe Adrenocorticotrophic Hormone-dependent Cushing’s disease, unresolved following hypophysectomy. In all patients, there was a resolution of hypercortisolaeemia, as well as Cushingoid clinical features following ablation. However, there is no long-term follow-up of disease recurrence [69]. Adrenal thermal ablation of pheochromocytoma has had variable success. Hypertensive crisis (HTC) arising from tumoral degranulation of stored catecholamine has had variable success. Hypertensive crisis (HTC) arising from tumoral degranulation of stored catecholamine has had variable success. Hypertensive crisis (HTC) arising from tumoral degranulation of stored catecholamine has had variable success.

**METASTATIC CANCERS OF THE ADRENAL**

Localised therapy is now recommended for the management of metastatic tumour bulk in patients with ACC [71]. Evidence for this approach is evolving for metastatic adrenal malignancy, albeit that it is a well-healed modality for disease control in other malignancies [12]. Most recently, a single case series of 16 patients has described efficacy of CT-guided RFA to the liver and lung for oligometastatic ACC. The results of this study are encouraging, reporting radiological evidence of complete ablation in 97% of targeted lesions. Local progression was low and occurred in larger lesions, with an overall rate of 24% and a median local progression-free survival of 21 months [61**]. Single case studies have demonstrated efficacy of this approach for spinal metastasis from ACC [60**]. Similarly, localised therapy has been used to treat metastatic deposits from pheochromocytoma/paraganglioma (PGGL), not fully controlled with chemotherapy or Peptide Receptor Radionuclide Therapy alone [62,63**]. A recent case series described the outcomes of 31 patients with metastatic PGGL all of whom were alpha blocked for 7–14 days prior to ablation and treated with a combination of RFA, cryoablation or ethanol injection. Ablation of metastasis to bone, liver and pelvis achieved local control in 74–94%. Tumour progression was reported in 6–26% (median time to progression 16 months). Symptoms related to catecholamine excess also improved in patients treated using this modality and procedural HTC was reported in 14% [62,63**].

The data for both indications are promising and demonstrate the efficacy of palliative ablation of metastases arising from adrenal malignancy in experienced hands. However, ablating metastases within large organs is the traditional indication for thermal ablation and the indication for which currently approved technology has been optimised. This is in contrast to thermal ablation to the adrenal gland itself, which remains challenging.

**COMPLICATIONS**

HTC, arising from medullary degranulation represents the greatest risk of adrenal ablation irrespective of cortical or medullary aetiology [24**,57,63**]. The risk for medullary degranulation and transient catecholamine crisis is highlighted by two studies in swine that demonstrated transient hypertension and catecholamine crisis with respective use of
MWA and RFA to ablate normal adrenal glands. Catecholamine crisis occurred even when limited ablation of a small adrenal volume <1 cm³ was undertaken with minimal medullary destruction, indicating the risk for widespread medullary degranulation even in the presence of limited and localized insult [24**,72]. These findings have been borne out in human studies where HTC is demonstrated in as high as 57% of individuals undergoing ablation [57]. HTC is frequently accompanied by ventricular arrhythmia in the setting of catecholamine excess [48**]. In studies using preprocedural alpha adrenergic blockade, rates of HTC are reduced significantly for ablation of adrenocortical lesions (Table 2) [63**]. Therefore, peri-procedural alpha blockade should be routinely undertaken for all thermal ablation procedures to the adrenal gland. Additionally, adrenal ablation should only be undertaken following firm biochemical diagnosis of the underlying lesion. Specifically, ablation of large primary phaeochromocytomas should reserved for exceptional conditions, where gold-standard therapeutic approach is not possible. and performed following adequate preprocedural alpha adrenergic blockade and with peri-procedural anaesthetic support. HTC mandating procedural stoppage and emergency pharmacological intervention adversely impacts patient safety and therapeutic outcome, as well as carrying significant health economic implications [40].

Technical complications and structural damage are slightly higher for adrenal ablation when compared to ablation in other organs, due to the narrow window of approach [33]. These include pneumothorax [39,51,54,57], haemorrhage, vascular thrombosis and visceral perforation [11,39,54,61**,62,63**] (Table 2). Where patients with Cushing’s syndrome have been treated, adrenocortical insufficiency, as expected has occurred [53]. Pain is a common minor complication of RFA that requires anaesthetic or sedation, and occurs less frequently with the use of MWA [5].

**TECHNICAL CHALLENGES AND IMAGE-GUIDED APPROACHES**

Ablation of the adrenal gland remains a highly skilled procedure and presents greater technical challenges for the operator when compared to hepatic or renal ablation [33]. Most currently available thermal ablation technology is not engineered with adrenal therapeutics in mind. At present, approved RFA and MWA delivery systems are engineered to treat malignancy within large organs, aiming to ablate large tissue volumes, i.e., targeted tumour plus margins [5,19]. The adrenal is a small gland, affected predominantly by benign adenomas. Ideal application of adrenal thermal ablation should aim to (i) selectively ablate the offending tumour, while (ii) avoiding nearby critical structures and simultaneously (iii) preserving adjacent normal adrenal, thus minimising the risk of adrenocortical insufficiency and peri-procedural hypertensive catecholamine crisis. To optimally achieve these therapeutic outcomes mandates the specific design of appropriate applicator antennae [24**].

Current image-guidance for adrenal ablation favours CT fluoroscopy over ultrasound [33]. This imaging modality offers clearer visualisation of the adrenals and critically also identifies adjacent structures, such as lung, colon and major vessels e.g. the splenic artery and the inferior vena cava. Ultrasound does not provide adequate resolution of the adrenal nor the surrounding structures to safely inform probe placement for adrenal ablation [73]. Moreover, ultrasound imaging is further hampered by steam generation during the thermal ablation procedure itself [74]. Nonetheless, some investigators have advocated an approach to the left adrenal gland using endoscopic ultrasound [75]. During CT fluoroscopy, patients are placed in the prone or ipsilateral decubitus position [48**,76]. The former provides the largest approach window and minimises the contact between the adrenal and adjacent organs. The latter reduces respiratory excursion of the diaphragm and reduces the pleural path, thereby minimising the risk for pneumothorax [77]. Hydrodissection can be used in order to increase the space between the targeted adrenal and adjacent critical structures [78]. Advance treatment planning between the interventional radiologist and endocrinologist is recommended in order to inform the optimum approach with will maximise therapeutic efficacy and patient safety.

**FUTURE DIRECTIONS FOR THERMAL ABLATION OF ADRENAL DISORDERS**

Thermal ablation, as a therapeutic approach to adrenal tumours is in its infancy and does not yet represent a feasible routine alternative to gold-standard adrenalectomy. High quality supporting evidence for the use of adrenal ablation is not yet available and as such randomized controlled trials and direct head-to-head comparisons with surgery are necessary to fully evaluate its benefit. Undoubtedly thermal ablation offers promise to increase the scope for delivery of definitive therapy for adrenal endocrinopathies in unilateral and perhaps bilateral disease [24**,69,79]. However, significant challenges remain in the development of the technology. Current off-the-shelf ablation systems need to undergo
Adrenal cortex and medulla

design modifications to facilitate safer approach to the adrenal and to provide precision selective ablation of adrenal adenomas. Recent animal studies suggest that side-firing probes may offer superior precision for ablation of adrenal lesions [19,21,24**,25**,26*,28,29**,31,80].

Development of precision treatment planning systems is also necessary. This should incorporate the following (i) high resolution structural imaging, to inform the window of approach [64]; (ii) functional [42,81] imaging, to identify the intra-adrenal target and (iii) preprocedural computerized simulation [22] of thermal ablation pattern, to inform the dose and duration of ablation. Many of the elements to develop proper treatment planning exist, such as high resolution structural imaging and simulators. However, reliable functioning imaging of adrenocortical lesions remains a challenge, and modalities such as 11C Metomidate PET/CT are not widely available [42,81].

The management of metastatic lesions arising from adrenal malignancy is also an exciting area for further investigation. The immune editing capability of thermal ablation has not been studied in this context specifically for adrenal disease. However, emerging data in other malignancies have demonstrated regression of multiple remote metastases following thermal ablation of a single lesion [82]. A possible mechanism for this effect is the marked change in the immunological milieu of these metastases, which demonstrate a change in monocyte/macrophage polarization and a lymphocyte infiltration [17]. It has been suggested that in this regard, thermal ablation may increase the sensitivity of therapy-resistant metastases to immune checkpoint inhibitors [83]. This represents an exciting prospect for investigation in the context of improving treatment response to immune therapy for lymphocyte poor ACC [84].

CONCLUSION

In summary, thermal ablation of adrenal disease, while in its infancy shows promise but requires significant evidence generation to support its use. With technological advance and improved systems for treatment planning, this modality offers potential to shift the paradigm whereby we approach definitive management of adrenal endocrinopathy, as well as improving the prognosis and overall survival of patients with widespread ACC and PGGL.

Acknowledgements

We thank Anna Bottiglieri, Laura Farina, Kate Warde, and Nathan Mullen for their input and advice. We also thank Punit Prakash, Faraz Chamani, and Austin Pfannenstiel for contributing the mathematical model images.

Financial support and sponsorship

This work is supported by the National Institutes of Health (NIH) and Science Foundation Ireland.

Conflicts of interest

M.C.D. is currently receiving a grant from the National Institutes of Health (NIH) and Science Foundation Ireland. P.T.D. is carrying out work funded by the National Institutes of Health (NIH) and Science Foundation Ireland.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

* of special interest
** of outstanding interest

1. Wolffram F, Lesser T. A simulation study of the HIFU ablation process on lung tumours, showing consequences of atypical acoustic properties in flooded lung. Z Med Phys 2019; 29:49–58.
2. Ito T, O.S. Nagamine S, et al. Radiofrequency ablation of breast cancer: a retrospective study. Clin Breast Cancer 2018; 18:495–500.
3. Chini EN, Brown MJ, Farrell MA, et al. Hypertensive crisis in a patient undergoing percutaneous radiofrequency ablation of an adrenal mass under general anesthesia. Anesth Analg 2004; 99:1867–1869, table of contents.
4. Glassberg MB, Ghosh S, Clymer JW, et al. Microwave ablation compared with radiofrequency ablation for treatment of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis. Oncol Targets Ther 2019; 12:6407–6438.
5. Gurusamy K, Corrigan N, Croft J, et al. Liver resection surgery versus thermal ablation for colorectal liver metastases (LAVA): study protocol for a randomised controlled trial. Trials 2018; 13:105.
6. Davidson B, G.K. Corrigan N, et al. Liver resection surgery compared with thermal ablation in high surgical risk patients with colorectal liver metastases: the LAVA international RCT. HEPATOBILIARY TECHNIQUE ASSESS. 2020; 24:1–38.
7. Beland MD, Mayo-Smith WW. Ablation of adrenal neoplasms. Abdom Imaging 2009; 34:589–592.
8. Liu SY, et al. Radiofrequency ablation for benign aldosterone-producing adenoma: a fearless technique to an old disease. Ann Surg 2010; 252:1058–1064.
9. Lim HK, Lee JH, Ha EJ, et al. Radiofrequency ablation of benign nonfunctioning thyroid nodules: 4-year follow-up results for 111 patients. Eur Radiol 2013; 23:1044–1049.
10. Diao Z, Liu X, Qian L, et al. Efficacy and its predictor in microwave ablation for severe secondary hyperparathyroidism in patients undergoing haemodialysis. Int J Hyperthermia 2016; 32:614–622.
11. Mayo-Smith WW, Dupuy DE. Adrenal neoplasms: CT-guided radiofrequency ablation-preliminary results. Radiology 2004; 231:225–230.
12. Nikfarjam M, Muradlihan V, Christophi C. Mechanisms of focal heat destruction of liver tumors. J Surg Res 2005; 127:208–223.
13. Chu KP, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer 2014; 14:199–208.
14. Dromi SA. Radiofrequency ablation induces antigen-presenting cell infiltration and amplification of weak tumor-induced immunity. Radiology 2009; 251:58–66.
15. Ruggetti A, Rahimi H, Rossi P, et al. Modulation of blood circulating immune cells by radiofrequency tumor ablation. J Exp Clin Cancer Res 2003; 22:247–250.
16. Anders HJ, Schaefer L. Beyond tissue injury-damage-associated molecular patterns, toll-like receptors, and inflammasomes also drive regeneration and fibrosis. J Am Soc Nephrol 2014; 25:1387–1400.
17. den Brok MHMG. In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res 2004; 64:4024–4029.
18. Hiroshi K. Strong CD8 T-cell responses against tumor-associated antigens prolonging the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma. J Gastroenterol 2010; 45:451–458.
Thermal ablation in adrenal disorders Donlon and Dennedy

46. Walz MK, Groeben H, Alesina PF. Single-access retroperitoneoscopic adre- nalectasy (SARA) versus conventional retroperitoneoscopic adrenalectomy (CORA): a case-control study. World J Surg 2010; 34:1386–1390.

47. Ishidoya S, Ito A, Saka K, et al. Laparoscopic partial versus total adrena-
lectomy for aldosterone producing tumor. J Urol 2005; 174:40–43.

48. Liu B, Mo C, Wang W, et al. Treatment outcomes of percutaneous radio-
frequency and percutaneous ablation for adrenal metastases: a re-

49. Provides an important analysis of the benefits of thermal therapy in comparison to adrenalectomy in adrenal metastasis.

50. Chen Y, Scholten A, Chomsik-Higgins K, et al. Risk factors associated with perioperative complications and prolonged length of stay after laparoscopic adrenalectomy. JAMA Surg 2018; 153:1036–1041.

51. Abbas A, Idriz S, Raffill NJ, et al. Image-guided ablation of Conn’s adenomas in the management of primary hyperaldosteronism. Clin Radiol 2013; 68:279–283.

52. Anma K, Yamakado K, Suzuki R, et al. Image-guided radiofrequency ablation for adrenocortical carcinoma with Cushing syndrome: outcomes after mean follow-up of 33 months. Urology 2007; 70:407–411.

53. Nish N, Tanaka J, Minagawa A. Cushing syndrome treated by radiofrequency ablation of adrenal gland adenoma. Jpn J Radiol 2012; 30:274–276.

54. Mendiatt-Lama M. Efficacy of radiofrequency ablation in the treatment of small functional adrenal neoplasms. Radiology 2011; 258:309–316.

55. Liu SY, Chu CC, Tsui TK, et al. Adrenal ablation for metastatic mass: CT-guided radiofrequency ablation—long-term results and recurrence rate. Radiology 2016; 281:625–634.

56. Sarwar A, Brock DR, Vaidya A, et al. Multiple outcomes following percuta-
nous radiofrequency ablation of unilateral aldosterone-producing adenoma: comparison with adrenalectomy. J Vasc Interv Radiol 2018; 29:961–967.

57. Steepfel D, Nunes TF, Giordano SE, et al. Radiofrequency ablation of functioning adrenal adenomas: preliminary clinical and laboratory data. J Vasc Interv Radiol 2015; 26:1459–1464.

58. Frank NE, Deye D, Tancali K, et al. Local control and survival after image-guided percutaneous ablation of adrenal metastases. J Vasc Interv Radiol 2018; 29:276–284.

59. Hoegawa T, Yamakodo K, Nakatsuka A, et al. Unresectable adrenal metas-
tases: clinical outcomes of radiofrequency ablation. Radiology 2015; 277:584–593.

60. FinteinM JF. Catecholamine surge during image guided ablation of adrenal gland metastases: predictors, consequences, and recommendations for management. J Vasc Interv Radiol 2015; 27:395–402.

61. Liu S. Successful treatment of metastatic adrenocortical carcinoma in the spine. Medicine 2019; 98:e18259.

62. Demonstrates the ability of thermal therapy to improve metastatic adrenocortical carcinoma patients quality of life.

63. Veltri A, Basile D, Calandra M, et al. Oligometastatic adrenocortical carcinoma: the role of image-guided thermal ablation. Eur Radiol 2020; 30:6958–6964. Demonstrates the benefit of thermal therapy in local control of adrenocortical carcinoma metastatic spread.

64. Deljou A, Kohlenberg JD, Weingarten TN, et al. Hemodynamic instability during percutaneous ablation of extraadrenal metastases of pheochromocy-
toma and paraganglioma: a case series. BMC Anesthesiol 2018; 18:158.

65. Kohlenberg J, Welch B, Hamidi O, et al. Efficacy and safety of ablative therapy in the treatment of patients with metastatic pheochromocytoma and para-
ganglioma. Cancers 2018; 11:195.

66. Demonstrates the need for prebiopsy adrenergic blockade in the treatment of any metastatic pheochromocytoma and paraganglioma.

67. Wolf FJ, Dupuy DE, Mazar JR, et al. Adrenal neoplasms: Effectiveness and safety of CT-guided ablation of 23 tumors in 22 patients. Eur J Radiol 2012; 81:1717–1723.

68. leradi AM, Carnevale A, Angieli SA, et al. Outcomes following minimally invasive image-guided percutaneous ablation of adrenal glands. Gland Surg 2020; 9:859–869.

69. Sacks BA, Sacks AC, Faintuch S. Radiofrequency ablation treatment for aldosterone-producing adenomas. Curr Opin Endocrinol Diabetes Obes 2017; 24:169–175.

70. Yang M-H, Tian Y-S, Huang Y-H, et al. Comparison of radiofrequency ablation versus laparoscopic adrenalectomy for benign aldosterone-producing ade-

71. Ren C, Liang P, Yu X-L, et al. Percutaneous microwave ablation of adrenal tumors under ultrasound guidance in 33 patients with 35 tumors: a single-

72. Espinosa De Yacza AE, Welch TL, Osipina NS, et al. Image-guided thermal ablation of adrenal metastases: hemodynamic and endocrine outcomes. Endocr Pract 2017; 23:132–140.

73. Fassnacht D, Dekkers OM, Els C, et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2018; 170:G1–G48.
Adrenal cortex and medulla

72. Yamakado K, Takaki H, Uchida K, et al. Adrenal radiofrequency ablation in swine: change in blood pressure and histopathologic analysis. Cardiovasc Intervent Radiol 2011; 34:839–844.
73. Slapa RZ, Dobruch-Sobczak JW, Kasperlik-Zaluska KaA. Standards of ultrasound imaging of the adrenal glands. J Ultrasound 2015; 15:377–387.
74. Goldberg SN. Image-guided tumor ablation: standardization. Vasc Interv Radiol 2009; 20:377–390.
75. Wu X. Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) as an alternative to left sided adrenalectomy in the treatment of primary aldosteronism. Endocr Abstr 2019; 65:12.
76. Venkatesan AM, Locklin J, Dupuy DE, et al. Percutaneous ablation of adrenal tumors. Tech Vasc Interv Radiol 2010; 13:99–99.
77. Odisio BC, Tam AL, Avinscher R, et al. CT-guided adrenal biopsy: comparison of ipsilateral decubitus versus prone patient positioning for biopsy approach. Eur Radiol 2012; 22:1233–1239.
78. Uppot RN, Gervais DA. Imaging-guided adrenal tumor ablation. Am J Roentgenol 2013; 200:1226–1233.
79. Yamakado K, Hiroshi A, Takaki H, et al. Adrenal metastasis from hepatocellular carcinoma: radiofrequency ablation combined with adrenal arterial chemoembolization in six patients. Am J Roentgenol 2009; 192:6.
80. McWilliams BT, Schnell EE, Curto S, et al. A Directional Interstitial Antenna for Microwave Tissue Ablation: Theoretical and Experimental Investigation. IEEE Trans Biomed Eng 2015; 62:2144–2150.
81. Burton T. Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET-CT) for lateralizing aldosterone secretion by Conn’s adenomas. J Clin Endocrinol Metab 2012; 97:100–109.
82. Kim H, Park BK, Kim CK. Spontaneous regression of pulmonary and adrenal metastases following percutaneous radiofrequency ablation of a recurrent renal cell carcinoma. Korean J Radiol 2008; 9:470–472.
83. Mehta A, Oklu R, Sheth RA. Thermal ablative therapies and immune checkpoint modulation: can locoregional approaches effect a systemic response? Gastroenterol Res Pract 2016; 2016:9251375. doi: 10.1155/2016/9251375.
84. Landwehr LS, Aferi B, Schreiner J, et al. Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma. J Immunother Cancer 2020; 8:e000469. doi:10.1136/jitc-2019-000469.